Chinese Academy of Medical Sciences
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2004-07-08
- Employees
- -
- Market Cap
- -
Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy for Locally Advanced Esophageal Carcinoma
- Conditions
- Esophageal Neoplasms
- Interventions
- Radiation: IMRT simultaneous integrated boostProcedure: Esophagectomy
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT02429622
- Locations
- 🇨🇳
Zefen Xiao, Beijing, Beijing, China
Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT02403544
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
GDP in Frontline Chemotherapy for Patients With PTCL-NOS
- Conditions
- Lymphoma, T-Cell, Peripheral
- Interventions
- Drug: GDP chemotherapy
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 28
- Registration Number
- NCT02404571
- Locations
- 🇨🇳
Cancer Hospital and Institute, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, Beijing, China
Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2015-02-25
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 2
- Registration Number
- NCT02370849
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Traditional Three Incisions vs Minimally Invasive Thoracol-laparoscopic Esophagectomy for Esophageal Cancer
- Conditions
- Esophageal Carcinoma
- Interventions
- Procedure: OEProcedure: MIE
- First Posted Date
- 2015-02-04
- Last Posted Date
- 2015-02-04
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 648
- Registration Number
- NCT02355249
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳Quanzhou First Hospital, Quanzhou, Fujian, China
Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer
- Conditions
- Extensive-stage Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 62
- Registration Number
- NCT02323737
- Locations
- 🇨🇳
Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China
Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial
- First Posted Date
- 2014-12-18
- Last Posted Date
- 2015-08-03
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 240
- Registration Number
- NCT02319187
- Locations
- 🇨🇳
Hunan Cancer Hospital,the Affiliated Cancer Hospital of Xianya School of Medicine, Changsha, China
🇨🇳Herbin Medical University Cancer Hospital, Herbin, China
🇨🇳Henan Cancer Hospital, Zhengzhou, China
Everolimus trIal for Advanced prememopausaL Breast Cancer Patients
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2014-12-09
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 200
- Registration Number
- NCT02313051
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Observational Study on the Patients With Rectal Cancer
- Conditions
- Adjuvant ChemotherapyRectal CancerSurgeryAdjuvant ChemoradiotherapyNeoadjuvant Chemoradiotherapy
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 3995
- Registration Number
- NCT02312284
- Locations
- 🇨🇳
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China
A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiotherapy in Gastric Adenocarcinoma
- Conditions
- ChemoradiotherapyChemotherapyNeoadjuvant TherapyStomach Neoplasms
- Interventions
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2019-10-16
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 71
- Registration Number
- NCT02301481
- Locations
- 🇨🇳
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China